Peregrine Pharmaceuticals Doses First Patient in Bavituximab Trial: "Peregrine Pharmaceuticals has begun evaluating the safety and efficacy of bavituximab in combination with docetaxel in a Phase II trial of patients with advanced breast cancer.
The primary objective of the study, which is being conducted in the Republic of Georgia, will be to assess the overall response rate to the combination."